FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226341214> ?p ?o ?g. }

• W4226341214 abstract "British Journal of DermatologyVolume 186, Issue 4 p. e175-e175 Plain Language SummaryFree Access Guidelines on how to manage cutaneous lupus erythematosus First published: 04 April 2022 https://doi.org/10.1111/bjd.21069AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Linked article: O’Kane et al. Br J Dermatol 2021; 185:1112–1123 Cutaneous lupus erythematous (CLE) refers to a range of skin conditions with common clinical and laboratory findings. CLE is caused by a combination of genetic factors, autoantibodies and the environment, and can occur alone or as a feature of systemic lupus erythematosus (SLE). The British Association of Dermatologists put together a group that included consultant dermatologists, a consultant rheumatologist and patient representatives to review published evidence on treating adults, young people and children with CLE. The UK-based group produced 53 recommendations, based on a review of the evidence, for the management of CLE in general practitioner clinics and in hospitals. They used an approach called the GRADE system (Grading of Recommendations Assessment, Development and Evaluation) for developing guidelines. General measures central to the management of CLE include sun protection and smoking avoidance. The possibility of drug-induced CLE should be considered, and medications that might potentially be the culprit stopped. Where the psychological impact of CLE on a patient is significant, referral to psychological support services should be considered. Topical steroids are an appropriate first-line medication for localized CLE. However, in active or widespread CLE, oral medications should be introduced early, with antimalarial drugs (such as hydroxychloroquine) being the first choice in most cases. The recommended patient management pathway for CLE is presented as a flow diagram to guide clinicians through options for first-line, second-line and third-line treatments. Recommendations for future research and audit points (to help check the care of patients with CLE is meeting the right standards) are also included. Volume186, Issue4April 2022Pages e175-e175 RelatedInformation" @default.
• W4226341214 created "2022-05-05" @default.
• W4226341214 date "2022-04-01" @default.
• W4226341214 modified "2023-10-18" @default.
• W4226341214 title "Guidelines on how to manage cutaneous lupus erythematosus" @default.
• W4226341214 doi "https://doi.org/10.1111/bjd.21069" @default.
• W4226341214 hasPublicationYear "2022" @default.
• W4226341214 type Work @default.
• W4226341214 citedByCount "0" @default.
• W4226341214 crossrefType "journal-article" @default.
• W4226341214 hasBestOaLocation W42263412141 @default.
• W4226341214 hasConcept C127413603 @default.
• W4226341214 hasConcept C142724271 @default.
• W4226341214 hasConcept C147176958 @default.
• W4226341214 hasConcept C159654299 @default.
• W4226341214 hasConcept C16005928 @default.
• W4226341214 hasConcept C161191863 @default.
• W4226341214 hasConcept C203014093 @default.
• W4226341214 hasConcept C2775915377 @default.
• W4226341214 hasConcept C2776912625 @default.
• W4226341214 hasConcept C2777286243 @default.
• W4226341214 hasConcept C2778805511 @default.
• W4226341214 hasConcept C2779134260 @default.
• W4226341214 hasConcept C2911091503 @default.
• W4226341214 hasConcept C41008148 @default.
• W4226341214 hasConcept C512399662 @default.
• W4226341214 hasConcept C71924100 @default.
• W4226341214 hasConceptScore W4226341214C127413603 @default.
• W4226341214 hasConceptScore W4226341214C142724271 @default.
• W4226341214 hasConceptScore W4226341214C147176958 @default.
• W4226341214 hasConceptScore W4226341214C159654299 @default.
• W4226341214 hasConceptScore W4226341214C16005928 @default.
• W4226341214 hasConceptScore W4226341214C161191863 @default.
• W4226341214 hasConceptScore W4226341214C203014093 @default.
• W4226341214 hasConceptScore W4226341214C2775915377 @default.
• W4226341214 hasConceptScore W4226341214C2776912625 @default.
• W4226341214 hasConceptScore W4226341214C2777286243 @default.
• W4226341214 hasConceptScore W4226341214C2778805511 @default.
• W4226341214 hasConceptScore W4226341214C2779134260 @default.
• W4226341214 hasConceptScore W4226341214C2911091503 @default.
• W4226341214 hasConceptScore W4226341214C41008148 @default.
• W4226341214 hasConceptScore W4226341214C512399662 @default.
• W4226341214 hasConceptScore W4226341214C71924100 @default.
• W4226341214 hasIssue "4" @default.
• W4226341214 hasLocation W42263412141 @default.
• W4226341214 hasOpenAccess W4226341214 @default.
• W4226341214 hasPrimaryLocation W42263412141 @default.
• W4226341214 hasRelatedWork W2055721954 @default.
• W4226341214 hasRelatedWork W2086557629 @default.
• W4226341214 hasRelatedWork W2328000965 @default.
• W4226341214 hasRelatedWork W2339688819 @default.
• W4226341214 hasRelatedWork W2406477627 @default.
• W4226341214 hasRelatedWork W2802178498 @default.
• W4226341214 hasRelatedWork W2988577341 @default.
• W4226341214 hasRelatedWork W3023730235 @default.
• W4226341214 hasRelatedWork W3110736461 @default.
• W4226341214 hasRelatedWork W4224313059 @default.
• W4226341214 hasVolume "186" @default.
• W4226341214 isParatext "false" @default.
• W4226341214 isRetracted "false" @default.
• W4226341214 workType "article" @default.